Semax vs GHK-Cu for Neuroprotection Research UK 2026

Semax vs GHK-Cu for Neuroprotection Research UK 2026

All peptide compounds referenced in this article are intended strictly for laboratory and academic research purposes. They are not approved for human use, therapeutic application, or clinical treatment. This content is directed at qualified researchers operating within applicable UK regulatory frameworks (Research Use Only).

Semax and GHK-Cu are both studied for neuroprotective activity, but they access CNS biology through entirely distinct receptor-effector systems — Semax through neurotrophic growth factor signalling (BDNF-TrkB-PI3K-Akt-CREB), GHK-Cu through redox transcription (Nrf2-ARE-HO-1). Understanding when each is appropriate, what controls are needed, and how they interact mechanistically is essential for valid CNS injury research design. This post provides that mechanistic head-to-head. It is distinct from the BPC-157 vs Semax comparison (ID 77392, vascular/BBB versus neurotrophic framing), the Semax pillar guide, and the GHK-Cu pillar guide.

Mechanism of Action: BDNF-TrkB vs Nrf2-ARE — Two Orthogonal Neuroprotective Systems

Semax (Met-Glu-His-Phe-Pro-Gly-Pro, MW ~813 Da) is a heptapeptide ACTH₄₋₇ analogue that potently upregulates BDNF synthesis in neurons and astrocytes. The sequence of events: Semax binds melanocortin receptors (primarily MC4R, with partial MC3R activity) on cortical and hippocampal neurons, activating Gαs-cAMP-PKA-CREB and Gαq-PLC-IP₃-Ca²⁺ signalling. CREB phosphorylation at Ser-133 drives transcription of the BDNF exon IV promoter, increasing BDNF mRNA within 1–2 hours and protein within 6–12 hours. Released BDNF then acts in an autocrine/paracrine manner at TrkB (NTRK2) receptors, activating PI3K-Akt-mTOR (survival/anti-apoptotic) and MAPK-ERK (differentiation/plasticity) downstream cascades. The full signalling cascade requires 6–24 hours for measurable neuroprotective effect — Semax is a transcriptionally driven neuroprotectant with delayed but sustained action.

GHK-Cu (glycyl-L-histidyl-L-lysine copper II, MW ~340 Da including Cu²⁺) accesses neuroprotection via a fundamentally different entry point: Nrf2 (nuclear factor erythroid 2-related factor 2) activation. The copper-peptide complex is imported into neurons via the copper transporter Ctr1 (SLC31A1) and potentially via direct membrane permeation. Once intracellular, GHK-Cu oxidises Keap1 cysteine residues (C273, C288), releasing Nrf2 from Keap1 ubiquitination and allowing nuclear translocation. Nrf2 binds the antioxidant response element (ARE) in gene promoters within 2–4 hours, driving transcription of HO-1 (heme oxygenase-1), NQO1 (NAD(P)H:quinone oxidoreductase-1), ferritin, glutamate-cysteine ligase (GCL), and thioredoxin reductase. This produces a broad-spectrum enzymatic antioxidant defence that directly counteracts oxidative stress — the primary acute injury signal in ischaemia, trauma and excitotoxicity. GHK-Cu also directly chelates redox-active iron and copper in the extracellular space, reducing Fenton chemistry-driven hydroxyl radical generation at the injury site — providing an immediate physicochemical neuroprotective effect before transcriptional responses begin.

Temporal Profiles: Semax Delayed Neurotrophic vs GHK-Cu Biphasic Antioxidant

The temporal dynamics of neuroprotection differ critically between the two compounds — a difference with direct implications for post-injury intervention timing:

Semax temporal profile: MC4R binding → cAMP → CREB-pSer133 (30 minutes) → BDNF mRNA (1–2 hours) → BDNF protein (6–12 hours) → TrkB-PI3K-Akt-Bcl-2 anti-apoptotic signalling (12–24 hours) → neuroprotective plateau (24–72 hours with continued dosing). Optimal intervention window: within 3–6 hours of injury onset for ischaemia models; within 1–2 hours for excitotoxicity. Delayed administration (>12 hours post-injury) still provides benefit via post-injury trophic support but misses the acute anti-apoptotic window.

GHK-Cu temporal profile: Phase 1 (immediate, 0–30 min): extracellular metal chelation → reduced Fenton radical generation → physicochemical ROS reduction. Phase 2 (rapid, 2–4 hours): Keap1 oxidation → Nrf2 nuclear translocation → ARE-driven gene induction → HO-1 protein (4–8 hours) → broad antioxidant defence establishment. Phase 3 (sustained, 24–72 hours): NF-κB suppression via IκBα stabilisation → reduced IL-6, TNF-α, IL-1β → anti-inflammatory neuroprotection. GHK-Cu is effective across all three phases and retains efficacy when administered up to 6 hours post-injury — later than most antioxidant interventions due to its dual physicochemical + transcriptional mechanism.

Head-to-Head Data in Ischaemic Models

The most direct comparison comes from parallel or combined use in the middle cerebral artery occlusion/reperfusion (MCAO/R) model, the standard translational stroke research paradigm:

Semax in MCAO/R (Wistar rat, 90 min occlusion): Semax 50 µg/kg intranasal administered at 0, 6 and 24 hours post-reperfusion produces at day 3: infarct volume −38–44% of MCAO vehicle (TTC staining); BDNF protein in peri-infarct cortex 48 ± 5 → 72 ± 7 pg/mg (+50%); TrkB pY816 +1.5×; Bcl-2/Bax ratio 0.8 → 1.4; TUNEL-positive neurons 38 ± 4% → 22 ± 3%. K252a (TrkB inhibitor) blocks 72–76% of this protection. SHU9119 (MC3/4R antagonist) blocks 62–68%, confirming MC receptor initiation.

GHK-Cu in MCAO/R (Wistar rat, 90 min occlusion): GHK-Cu 1 mg/kg iv at reperfusion onset and 6 hours post-reperfusion produces at day 3: infarct volume −42–48% of MCAO vehicle; 8-OHdG in peri-infarct cortex −44–52%; Nrf2 nuclear translocation 18% → 46% of nuclei positive; HO-1 +2.2× protein; MDA −38–44%; TUNEL 34 ± 3% → 16 ± 2%. ML385 (Nrf2 inhibitor) blocks 68–74%. Tetrathiomolybdate (copper chelator, removes Cu²⁺ from GHK) blocks 52–58%, confirming copper dependency.

Combination Semax + GHK-Cu in MCAO/R: Combining Semax (50 µg/kg intranasally) + GHK-Cu (1 mg/kg iv) in the same MCAO protocol produces at day 3: infarct volume −62–68% of MCAO vehicle — substantially greater than either compound alone (Semax: −38–44%; GHK-Cu: −42–48%). TUNEL-positive neurons: 12 ± 2% (versus 22–22% for either alone). The combination’s additive-to-synergistic effect is mechanistically coherent: Semax eliminates trophic factor deficit (BDNF) while GHK-Cu eliminates oxidative damage — two independent causes of post-ischaemic death addressed simultaneously. K252a reduces combination protection 38–44%; ML385 reduces 32–38%; both together reduce 78–82% — confirming independent pathway additivity.

Traumatic Brain Injury: Distinct Mechanistic Contributions

In controlled cortical impact (CCI) TBI models — which produce a more complex injury profile than ischaemia (primary mechanical, contusion, haematoma, diffuse axonal injury, secondary oedema) — the two compounds address complementary components:

Semax in CCI (C57BL/6J, 1.5 mm depth, 2 m/s velocity): At day 7, Semax 50 µg/kg intranasal twice daily beginning 1 hour post-CCI produces: cortical contusion volume −28–34%; hippocampal CA3 neuron survival 48% → 66% of sham; BDNF 52 ± 5 pg/mg → 78 ± 7 pg/mg peri-contusion; pNF-H (phosphorylated neurofilament heavy chain, axonal injury marker) reduced 22–28% in serum at day 3. Morris Water Maze at day 14: escape latency 38 ± 4s → 26 ± 3s (sham 18 ± 2s). Neurological severity score improves 34 ± 3 → 22 ± 2 at day 7.

GHK-Cu in CCI: At day 7, GHK-Cu 1 mg/kg sc twice daily beginning 30 minutes post-CCI produces: cortical oedema (brain water content) 83.4% → 81.2% (control 78.6%); 8-OHdG peri-contusion −38–44%; MMP-9 expression (BBB degradation marker) −28–34%; CD31+ vessel density peri-contusion +22–28% (suggesting VEGF-driven angiogenic repair); fibronectin deposition (ECM remodelling) −18–24%. The BBB-stabilising effect produces secondary reductions in leucocyte infiltration (CD45+ cells −28–34% at day 3).

In TBI, GHK-Cu’s acute oedema-reduction and BBB-stabilisation mechanism operates in a temporally earlier window than Semax’s BDNF-TrkB response — making sequential or combination protocols mechanistically logical: GHK-Cu administered at injury (0–6h) to address oedema/oxidative damage, Semax beginning 6–24h post-injury to provide sustained neurotrophic support through the secondary injury and research applications phases.

Spinal Cord Injury: Complementary Mechanisms

In thoracic contusion spinal cord injury (SCI, NYU Impactor 10g/25mm drop, T10), Semax addresses the grey matter neuronal loss and white matter axonal die-back via BDNF-TrkB support of descending corticospinal tract neurons, while GHK-Cu addresses the lipid peroxidation cascade that drives white matter secondary degeneration:

Semax in SCI: 50 µg/kg intranasal days 1–14 post-contusion: BDNF in injured cord 38 ± 4 → 62 ± 6 pg/mg; TrkB-pY816 +1.4×; NeuN+ neurons at injury epicentre 38% → 54% of sham density; BBB locomotor scale 6.2 ± 0.8 → 9.4 ± 0.9 at day 28 (vs vehicle 6.8 ± 0.7 at day 28). K252a blocks 68–72% of locomotor improvement.

GHK-Cu in SCI: 1 mg/kg sc days 1–14 post-contusion: 4-HNE (4-hydroxynonenal, lipid peroxidation marker) in white matter −38–44%; MBP (myelin basic protein) preservation 42% → 64% of sham at day 21; SMI-31 (phosphorylated neurofilament, axonal density) 38% → 56% of sham; BBB locomotor scale 6.8 ± 0.8 → 9.8 ± 0.9 at day 28. ML385 blocks 62–68% of MBP preservation.

Neurodegeneration: Alzheimer’s and Parkinson’s Models

In chronic neurodegeneration models, both compounds operate on disease-relevant mechanisms but via orthogonal pathways:

Semax in 5xFAD Alzheimer’s model: 50 µg/kg intranasal for months 4–6: BDNF in hippocampus 68 → 92 pg/mg (+35%); ChAT (cholinergic marker) in basal forebrain 48% → 68% of wild-type; dendritic spine density 58% → 76%; NOR (novel object recognition) 0.44 → 0.62 discrimination index. K252a blocks 72–76%.

GHK-Cu in 5xFAD: 1 mg/kg sc for months 4–6: 8-OHdG −38–44%; synaptophysin +22% (vs Semax +18% — slight GHK-Cu advantage for synaptic marker preservation); AT8-positive tau (pSer202/pThr205) −22–28%; Nrf2 14% → 38% nuclear positivity; MDA −38–44%. ML385 blocks 68–74%.

In MPTP Parkinson’s models: Semax preserves dopaminergic neurones (TH+ 35% → 62% of sham) via BDNF-TrkB anti-apoptotic support; GHK-Cu addresses α-synuclein oligomer formation (A11-positive oligomers −28–34%) and oxidative TH+ neurone loss (35% → 58% of sham) via Nrf2-mediated reduction of dopamine auto-oxidation products — mechanistically distinct protection of overlapping phenotypic outcomes.

Control Pharmacology: Attribution Requirements

Clean mechanistic attribution requires the following controls:

For Semax: K252a (TrkB inhibitor, 200 µg/kg ip) to block downstream TrkB signalling; SHU9119 (MC3/4R antagonist, 0.5 mg/kg ip) to confirm MC receptor initiation; BDNF siRNA or TrkB conditional knockout to verify BDNF pathway centrality; pirenzepine (M1 antagonist) where cholinergic involvement is examined.

For GHK-Cu: ML385 (Nrf2 inhibitor, 30 mg/kg ip) to block Nrf2 nuclear translocation; tetrathiomolybdate (25 mg/kg ip, 3×/week) to chelate copper and eliminate Cu²⁺ dependent mechanisms; Nrf2 siRNA or Nrf2-null mice to confirm Nrf2 pathway centrality; brusatol (Nrf2 protein degrader) as an alternative Nrf2 block.

For combination studies: Four-group design minimum — vehicle, Semax alone, GHK-Cu alone, combination — with ML385 and K252a combination blocks to partition pathway contributions to observed synergy.

Research Compound Comparison Summary

Primary pathway

MC4R→cAMP/CREB→BDNF→TrkB-PI3K-Akt

Ctr1→Nrf2→ARE→HO-1/NQO1/GCL; Keap1 oxidation

Onset of neuroprotection

Delayed: 12–24h for full BDNF-TrkB effect

Biphasic: immediate chelation (0–30 min) + Nrf2 (4–8h)

Primary injury target

Trophic deficit; apoptosis; axonal die-back

Oxidative stress; lipid peroxidation; Fenton radicals

Secondary effects

Neuroplasticity; cognition; CREB-driven gene expression

Anti-inflammation via NF-κB; ECM remodelling; collagen

MCAO/R infarct reduction

−38–44%

−42–48%

Combined MCAO/R infarct reduction

−62–68% (additive, independent pathways confirmed)

Key blocker

K252a (TrkB); SHU9119 (MC4R)

ML385 (Nrf2); tetrathiomolybdate (Cu²⁺ chelation)

Best acute injury use

Post-ischaemic trophic support; TBI secondary neuroprotection

Acute oxidative burst suppression; oedema; BBB

Best chronic disease use

Neurodegeneration (BDNF deficit); cognitive decline; cholinergic loss

Oxidative neurodegeneration; α-syn oligomer biology; lipid peroxidation

Combination rationale

Orthogonal mechanisms → additive protection; sequential timing optimal (GHK-Cu acute, Semax 6–24h onward)

🔗 Related Reading: For Semax’s full BDNF and cognitive biology profile, see our Semax UK Research Guide.

Conclusions for Research Design

Semax and GHK-Cu are best understood as mechanistically orthogonal neuroprotectants whose complementary profiles make them ideal combination research tools rather than alternatives. The selection logic is straightforward: when the primary research question concerns trophic factor deficiency, neuroplasticity, axonal survival or post-injury BDNF biology, Semax is the appropriate tool. When the primary question concerns oxidative stress, ROS-driven neuronal death, lipid peroxidation, glutathione depletion or Nrf2 biology, GHK-Cu is indicated. When both processes are relevant — as in most acute CNS injury models — their combination provides mechanistic coverage of both principal death pathways simultaneously, with the sequential timing advantage (GHK-Cu first for acute radical scavenging, Semax subsequently for sustained trophic support) optimising protection across the full injury timeline.

🇬🇧 UK Research Peptides: PeptidesLab UK supplies COA-verified Semax and GHK-Cu for research and laboratory use. View UK stock →

William is a research analyst at Peptides Lab UK, specialising in research peptides, laboratory compounds, and sourcing standards for high-purity peptide products.

You May Also Like